ESH Position Paper: Renal denervation-an interventional therapy of resistant hypertension

Roland E. Schmieder, Josep Redon, Guido Grassi, Sverre E. Kjeldsen, Giuseppe Mancia, Krzysztof Narkiewicz, Gianfranco Parati, Luis Ruilope, Philippe Van De Borne, Costas Tsioufis

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.

Original languageEnglish
Pages (from-to)837-841
Number of pages5
JournalJournal of Hypertension
Volume30
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Denervation
Hypertension
Kidney
Blood Pressure
Therapeutics
Catheters
Central Nervous System
Safety

Keywords

  • European Society of Hypertension
  • interventional therapy
  • resistant hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Schmieder, R. E., Redon, J., Grassi, G., Kjeldsen, S. E., Mancia, G., Narkiewicz, K., ... Tsioufis, C. (2012). ESH Position Paper: Renal denervation-an interventional therapy of resistant hypertension. Journal of Hypertension, 30(5), 837-841. https://doi.org/10.1097/HJH.0b013e328352ce78

ESH Position Paper : Renal denervation-an interventional therapy of resistant hypertension. / Schmieder, Roland E.; Redon, Josep; Grassi, Guido; Kjeldsen, Sverre E.; Mancia, Giuseppe; Narkiewicz, Krzysztof; Parati, Gianfranco; Ruilope, Luis; Van De Borne, Philippe; Tsioufis, Costas.

In: Journal of Hypertension, Vol. 30, No. 5, 05.2012, p. 837-841.

Research output: Contribution to journalArticle

Schmieder, RE, Redon, J, Grassi, G, Kjeldsen, SE, Mancia, G, Narkiewicz, K, Parati, G, Ruilope, L, Van De Borne, P & Tsioufis, C 2012, 'ESH Position Paper: Renal denervation-an interventional therapy of resistant hypertension', Journal of Hypertension, vol. 30, no. 5, pp. 837-841. https://doi.org/10.1097/HJH.0b013e328352ce78
Schmieder, Roland E. ; Redon, Josep ; Grassi, Guido ; Kjeldsen, Sverre E. ; Mancia, Giuseppe ; Narkiewicz, Krzysztof ; Parati, Gianfranco ; Ruilope, Luis ; Van De Borne, Philippe ; Tsioufis, Costas. / ESH Position Paper : Renal denervation-an interventional therapy of resistant hypertension. In: Journal of Hypertension. 2012 ; Vol. 30, No. 5. pp. 837-841.
@article{053e530a766d4bac8db4a7df100e935a,
title = "ESH Position Paper: Renal denervation-an interventional therapy of resistant hypertension",
abstract = "Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.",
keywords = "European Society of Hypertension, interventional therapy, resistant hypertension",
author = "Schmieder, {Roland E.} and Josep Redon and Guido Grassi and Kjeldsen, {Sverre E.} and Giuseppe Mancia and Krzysztof Narkiewicz and Gianfranco Parati and Luis Ruilope and {Van De Borne}, Philippe and Costas Tsioufis",
year = "2012",
month = "5",
doi = "10.1097/HJH.0b013e328352ce78",
language = "English",
volume = "30",
pages = "837--841",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - ESH Position Paper

T2 - Renal denervation-an interventional therapy of resistant hypertension

AU - Schmieder, Roland E.

AU - Redon, Josep

AU - Grassi, Guido

AU - Kjeldsen, Sverre E.

AU - Mancia, Giuseppe

AU - Narkiewicz, Krzysztof

AU - Parati, Gianfranco

AU - Ruilope, Luis

AU - Van De Borne, Philippe

AU - Tsioufis, Costas

PY - 2012/5

Y1 - 2012/5

N2 - Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.

AB - Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.

KW - European Society of Hypertension

KW - interventional therapy

KW - resistant hypertension

UR - http://www.scopus.com/inward/record.url?scp=84859898722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859898722&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e328352ce78

DO - 10.1097/HJH.0b013e328352ce78

M3 - Article

C2 - 22469838

AN - SCOPUS:84859898722

VL - 30

SP - 837

EP - 841

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 5

ER -